Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects.
Meijer SE, Halutz O, Adler A, Levytskyi K, Tau L, Dekel M, Cohen-Poradosu R, Katchman E, Shasha D, Ablin J, Choshen G, Jacob G, Wasserman A, Ingbir M, Cohen YC, Perry C, Ram R, Herishanu Y, Bar On Y, van Thijn E, Rutsinsky N, Harari S, Stern A, Ben-Ami R, Paran Y.
Meijer SE, et al. Among authors: levytskyi k.
J Infect Chemother. 2024 Mar;30(3):271-275. doi: 10.1016/j.jiac.2023.10.022. Epub 2023 Nov 7.
J Infect Chemother. 2024.
PMID: 37944697